Learn About Chromophobe Renal Cell Carcinoma

What is the definition of Chromophobe Renal Cell Carcinoma?
Chromophobe renal cell carcinoma is a rare subtype of the most common form of kidney cancer called renal cell carcinoma (RCC). This type of cancer forms in the cells lining the small tubules in the kidney. These tubules help filter waste from the blood, making urine.
Save information for later
Sign Up
What are the alternative names for Chromophobe Renal Cell Carcinoma?
  • Chromophobe renal cell carcinoma
  • CRCC
  • ChRCC
Who are the top Chromophobe Renal Cell Carcinoma Local Doctors?
Learn about our expert tiers
Learn more
What are the latest Chromophobe Renal Cell Carcinoma Clinical Trials?
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma

Summary: This research study will assess whether abemaciclib alone or in combination with MK-6482 are safe and effective in slowing down the growth of clear cell renal cell carcinoma (ccRCC). The names of the study drugs in this investigational combination are: Abemaciclib MK-6482

Match to trials
Find the right clinical trials for you in under a minute
Get started
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Summary: This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with monoclon...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Chromophobe Renal Cell Carcinoma?
Clear Cell Renal Cell Carcinoma, Diagnostic and Therapeutic Difficulties, Case Report and Literature Review.
Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial.
Tired of the same old research?
Check Latest Advances
A Case of Renal Anastomosing Hemangioma.